Evotec AG Receives Pre-Clinical Milestone Payment as Part of Its Discovery Alliance With Boehringer Ingelheim Corporation

HAMBURG, Germany, Aug. 18, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology programme and represents the fourteenth milestone achieved in this multi-year, multi-target collaboration.